A congressional committee has attached report language to a key annual defense bill that calls on military officials to pay greater attention to potential “access pathways” to psychedelic therapies for servicemembers.
Citing a psychedelics executive order signed by President Donald Trump in April, the House Armed Services Committee is urging Department of Defense (DOD) leaders to “remain informed of lawful research and access pathways relevant to post-traumatic stress disorder and other serious mental health conditions affecting servicemembers during post-deployment and transition periods, and members of the Reserve Components and National Guard who also serve as first responders.”
That includes studies on “psilocybin-containing investigational products, including naturally derived whole-mushroom formulations administered in structured therapeutic settings,” the report that the panel approved to be attached to the National Defense Authorization Act (NDAA) for Fiscal Year 2027 says.
The panel is directing the secretary of defense to issue a report by February 1, 2027 that assesses data on such trials, along with an assessment of “legal and regulatory requirements for expanded access,” including under Trump’s psychedelics executive order as well as a Right to Try law the president signed during his first term in office.
The secretary’s report would also need to include
Read full article on Marijuana Moment
